Comments
Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST
Bayer, Defence Therapeutics, Novavax - Major events
The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.
Read
Commented by Armin Schulz on May 14th, 2024 | 07:15 CEST
Nel ASA, dynaCERT, Plug Power - Growth in the hydrogen sector
The hydrogen market is currently experiencing an upswing, characterized by an increasing number of large orders and stronger demand for hydrogen technologies. One example of the momentum in this sector is the recent success of Canadian fuel cell manufacturer Ballard Power, which has received the largest order in its history from Polish bus manufacturer Solaris. This order, which includes the delivery of 1,000 fuel cell engines by 2027 to equip hydrogen buses, demonstrates the market's willingness to invest in sustainable and innovative mobility solutions. The German company Enapter increased its order intake in the first quarter by 730% compared to the previous year - reason enough to take a look at other hydrogen companies.
Read
Commented by Stefan Feulner on May 13th, 2024 | 06:30 CEST
Rheinmetall, Power Nickel, Bloom Energy - Will the rally continue?
After a brief pause in recent weeks, the rally in Germany's leading index, the DAX, has continued unabated, with the target of 19,000 points already in sight. Defense stocks remain the undisputed top performers. Another sector that has taken center stage in recent weeks is commodities. In addition to gold, silver and copper, the industrial metals lithium and nickel are also forming solid foundations for the next upward impulse. Corresponding companies were already running ahead of the base value.
Read
Commented by Juliane Zielonka on May 10th, 2024 | 09:45 CEST
Desert Gold, Fresenius, SMA Solar: Emerging industry leaders in gold, medicine and renewable energies - investment opportunities in focus
This year's growth sectors are medicine, renewable energies and, due to the numerous geopolitical tensions, gold. The price of the precious metal has already climbed by 18% since January. In addition to its inflation protection function as a portfolio hedge, gold is also used in jewellery manufacturing, the electronics industry, and medicine. An increase in global demand for gold in these sectors can increase the profitability of gold mining companies and offer investors attractive returns. Desert Gold Ventures is an emerging explorer with gold deposits in West Africa. The area has many lucrative features. In the medical sector, Fresenius announces the completion of its restructuring measures by taking a tough and logical step towards more growth. Companies like SMA Solar in Germany, focusing on solar production, must also factor in the consequences. Where are investment opportunities with predictable risk?
Read
Commented by Fabian Lorenz on May 9th, 2024 | 08:00 CEST
Stocks facing revaluation! Nel ASA, Bayer, Power Nickel with potential
Relief for Bayer. In the US, the Company has won a victory in the dispute over compensation for illnesses caused by the chemical PCB. Is it groundbreaking and the start of a revaluation of the share? A revaluation already seems to be underway at Power Nickel. Following sensational drilling results, the share price soared. Surprisingly, gold, silver and copper were also found. Against this backdrop, the share appears to be favorably valued. Does this also apply to Nel? After all, the share price has risen by around 20% in just a few weeks. Is there new hope for the hydrogen pioneer? Or are today's figures from industry peer Plug Power threatening a new sell-off?
Read
Commented by Juliane Zielonka on May 9th, 2024 | 07:15 CEST
Carbon Done Right, Varta, Siemens Energy - On the road to success with clean energy
The global energy transition requires active measures to tackle current environmental issues. Companies such as carbon credit trader Carbon Done Right are proving how a consistent focus on clean energy through environmentally friendly projects brings environmental and economic benefits. Their innovative use of AI to precisely monitor their tree inventories ensures complete traceability of their carbon credits, which creates trust with investors and buyer companies such as Microsoft. Innovations are urgently needed for economic success at VARTA AG. A large-scale battery research project based on common salt as an energy source is intended to bring the ailing company back into the profit zone. Siemens Energy is already one step ahead. The current balance sheet reflects the ongoing restructuring measures and tough cost-cutting measures to further advance clean energy technologies. But one thing is falling by the wayside...
Read
Commented by André Will-Laudien on May 9th, 2024 | 07:00 CEST
Biotech and pharma stocks finally follow suit! Novo Nordisk, Bayer, BioNTech, Vidac Pharma and Evotec on the buy list
Things looked very different at the beginning of the year. After a brilliant rally in the Nasdaq Biotech Index at the end of last year, investors thought the upswing could continue in 2024. So far, this hope has not been confirmed. The main focus for the industry is the refinancing conditions. These have gradually deteriorated, as stubborn inflation is keeping central bank interest rates high. And judging by the wording of central bankers, the next interest rate cut does not seem to be penciled in yet. However, if it happens in the summer, things will likely move quickly for the life sciences sector. Then a quick sector rotation is the order of the day! Here is our buy list for the upcoming event.
Read
Commented by Fabian Lorenz on May 8th, 2024 | 06:45 CEST
BUY RECOMMENDATIONS! Are Evotec, Super Micro Computer, and Royal Helium about to take off?
Evotec's share price has plummeted by around 50% this year. Consequently, the stock is among the year's losers. However, several buy recommendations are raising eyebrows. Is the turnaround imminent? The Royal Helium share is also ripe for a turnaround. The little-known noble gas is used in the defense industry, medical technology and for quantum computers, among other things. Royal Helium aims to transition from an explorer into a producer and has enlisted strong partners to achieve this. Will the share see a breakthrough after the ongoing capital increase? And what about Super Micro Computer? The AI high-flyer seems to have overcome its phase of weakness. Is it now heading for new all-time highs?
Read
Commented by André Will-Laudien on May 7th, 2024 | 08:45 CEST
Artificial intelligence is on the rise - Nvidia, Super Micro Computer, Mountain Alliance, and Microsoft in focus
What James Cameron envisioned as a horror movie in the 1980s with his film "Terminator" has now become a reality: "Machines are taking over thinking". Experts expect the use of artificial intelligence (AI) in digitally configurable processes to result in double-digit productivity gains over the next few years. Not since the introduction of industrial robots have there been such leaps. The flip side of the coin is that jobs are now being destroyed around the globe, as simple intellectual tasks that can be performed by machines will gradually be cut back. Standard services or digital control processes, such as those in call or quality centers, will be particularly affected. From this perspective, the stock market has already mapped out a megatrend for an entire decade and sent selected AI stocks through the roof accordingly. What should investors focus on now?
Read
Commented by Armin Schulz on May 7th, 2024 | 07:00 CEST
Novo Nordisk, Cardiol Therapeutics, Pfizer - Pharma Watchlist: Three top innovators
In the rapidly evolving world of biotechnology and the pharmaceutical industry, a single drug can make all the difference, especially when these drugs are unique. They have the potential to change the entire sector by setting new standards in therapy, addressing unmet medical needs, and ultimately improving the quality of life of countless patients worldwide. These drugs are often called blockbusters and generate revenue of more than USD 1 billion. Innovation often also means creating a moat against the competition. Today, we take a look at three companies that are pursuing unique approaches.
Read